PET Imaging of Estrogen Receptors for Gynecological Tumors
PET Imaging of Estrogen Receptors for Gynecological Tumors
复制标题
DOI：
10.1097/rlu.0000000000004258
复制
发表时间：
2022-05
影响因子：
10.6
通讯作者：
T. Tsujikawa;Akira Makino;T. Mori;H. Tsuyoshi;Y. Kiyono;Y. Yoshida;H. Okazawa
中科院分区：
文献类型：
--
作者：
T. Tsujikawa;Akira Makino;T. Mori;H. Tsuyoshi;Y. Kiyono;Y. Yoshida;H. Okazawa
摘要在过去的几十年中，18F-FDG PET已被用于妇科恶性肿瘤的诊断，并被认为在诊断转移性病变和局部复发的准确性以及评估治疗反应方面优于传统的成像方法。另一方面，一些妇科肿瘤，如子宫内膜癌和平滑肌瘤，以及乳腺癌是雌激素依赖性的，其中雌激素对其发展和进展至关重要。18F-FES是一种18F标记的雌二醇化合物，雌二醇是最具生物活性的雌激素类型，18F-FES PET已被广泛用于雌激素受体阳性乳腺癌患者的诊断、分期和治疗后随访。与肿瘤活检材料的体外评估相比，PET成像具有能够测量体内肿瘤行为、表征整个肿瘤负荷并捕获肿瘤表型异质性的优点。在这篇文章中，我们回顾了雌激素相关的妇科肿瘤的表型，而不是乳腺癌使用18F-FES PET和18F-FDG PET的额外价值证明在他们的诊断和鉴别。此外，还介绍了除18F-FES和18F-FDG外，其他PET示踪剂在评价雌激素相关妇科肿瘤中的应用前景。
Abstract In the past few decades, PET with 18F-FDG has been used for the diagnosis of gynecological malignancies and is considered to be superior to conventional imaging methods in diagnostic accuracy for detecting metastatic lesions and local recurrence and in evaluating the treatment response. On the other hand, several gynecological tumors, such as endometrial cancer and leiomyoma, and breast cancer are estrogen-dependent, in which estrogen is essential for their development and progression. 18F-FES is an 18F-labeled compound of estradiol, the most bioactive type of estrogen, and 18F-FES PET has been well-established for diagnosis, staging, and posttherapeutic follow-up in patients with estrogen receptor–positive breast cancer. Compared with in vitro assessment of tumor biopsy material, PET imaging has the advantages of being able to measure in vivo tumor behavior, characterize the entire tumor burden, and capture the heterogeneity of the tumor phenotype. In this article, we review the phenotyping of estrogen-related gynecological tumors other than breast cancer using 18F-FES PET and demonstrate the additional value of 18F-FES PET to 18F-FDG PET in their diagnosis and prognostication. Moreover, promising PET tracers other than 18F-FES and 18F-FDG for the evaluation of estrogen-related gynecological tumors are introduced.